Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Orthofix Medical (OFIX) EBITDA Margin (2016 - 2026)

Orthofix Medical has reported EBITDA Margin over the past 17 years, most recently at 9.53% for Q1 2026.

  • For the quarter ending Q1 2026, EBITDA Margin rose 3780.0% year-over-year to 9.53%, compared with a TTM value of 14.8% through Mar 2026, up 4914.0%, and an annual FY2025 reading of 14.45%, up 3171.0% over the prior year.
  • EBITDA Margin came in at 9.53% for Q1 2026, down from 17.24% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 128.16% in Q4 2022 to a low of 143.1% in Q4 2023.
  • Median EBITDA Margin over the past 5 years was 7.68% (2022), compared with a mean of 8.81%.
  • The sharpest move saw EBITDA Margin surged 15905bps in 2022, then plummeted -27126bps in 2023.
  • Over 5 years, EBITDA Margin stood at 128.16% in 2022, then crashed by -212bps to 143.1% in 2023, then grew by 12bps to 125.24% in 2024, then surged by 114bps to 17.24% in 2025, then crashed by -45bps to 9.53% in 2026.
  • Per Business Quant, the three most recent readings for OFIX's EBITDA Margin are 9.53% (Q1 2026), 17.24% (Q4 2025), and 16.79% (Q3 2025).